Bridging science and health policy in cardiovascular disease: focus on lipid management: A Report from a Session held during the 7th International Symposium on Multiple Risk Factors in Cardiovascular Diseases: Prevention and Intervention--Health Policy, in Venice, Italy, on 25 October, 2008.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Atella, VBrady, A
Catapano, A L
Critchley, J
Graham, I M
Hobbs, F D R
Leal, J
Lindgren, P
Vanuzzo, D
Volpe, M
Wood, D
Paoletti, R
Affiliation
Department of Economics, University of Rome Tor Vergata, Rome, Italy.Issue Date
2009-06-10MeSH
Cardiovascular DiseasesCost of Illness
Europe
Government
Health Policy
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Metabolism
Preventive Medicine
Public Health
Risk Factors
Science
World Health
Metadata
Show full item recordCitation
Bridging science and health policy in cardiovascular disease: focus on lipid management: A Report from a Session held during the 7th International Symposium on Multiple Risk Factors in Cardiovascular Diseases: Prevention and Intervention--Health Policy, in Venice, Italy, on 25 October, 2008. 2009, 10 (1):3-21 Atheroscler SupplPublisher
Atherosclerosis. SupplementsJournal
Atherosclerosis. SupplementsDOI
10.1016/S1567-5688(09)70003-0PubMed ID
19497553Abstract
In Europe, cardiovascular disease (CVD) represents the main cause of morbidity and mortality, costing countries euro 190 billion yearly (2006). CVD prevention remains unsatisfactory across Europe largely due to poor control of CVD risk factors (RFs), growing incidence of obesity and diabetes, and sedentary lifestyle/poor dietary habits. Hypercholesterolaemia is a proven CVD RF, and LDL-C lowering slows atherosclerotic progression and reduces major coronary events. Lipid-lowering therapy is cost-effective, and intensive treatment of high-risk patients further improves cost effectiveness. In Italy, models indicate that improved cholesterol management translates into potential yearly savings of euro 2.9-4 billion. Identifying and eliminating legislative and administrative barriers is essential to providing optimal lipid care to high-risk patients. Public health and government policy can influence clinical practice rapidly, and guideline endorsement via national health policy may reduce the CVD burden and change physician and patient behaviour. Action to reduce CVD burden should ideally include the integration of strategies to lower the incidence of major CV events, improvement in total CV risk estimation, database monitoring of CVD trends, and development of population educational initiatives on CVD prevention. Failure to bridge the gap between science and health policy, particularly in relation to lipid management, could result in missed opportunities to reverse the burgeoning epidemic of CVD in Europe.Item Type
ArticleLanguage
enISSN
1878-5050ae974a485f413a2113503eed53cd6c53
10.1016/S1567-5688(09)70003-0
Scopus Count
Collections
Related articles
- Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
- Authors: Cziraky MJ, Watson KE, Talbert RL
- Issue date: 2008 Oct
- The Lorenzini Foundation in a changing scenario of patient management.
- Authors: Peracino A, Paoletti R
- Issue date: 2009 Jun 10
- Cost-effectiveness of lipid-lowering treatment according to lipid level.
- Authors: Pilote L, Ho V, Lavoie F, Coupal L, Zowall H, Grover SA
- Issue date: 2005 Jun
- An overview of cardiovascular disease burden in the United States.
- Authors: Mensah GA, Brown DW
- Issue date: 2007 Jan-Feb